Biomarker analysis with next generation sequencer in pulmonary sarcomatoid carcinomas
Project/Area Number |
15K09164
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Respiratory organ internal medicine
|
Research Institution | Hokkaido University |
Principal Investigator |
OIZUMI SATOSHI 北海道大学, 医学研究院, 客員研究員 (10421968)
|
Project Period (FY) |
2015-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Keywords | 肺肉腫様癌 / 肺肉腫様 / ドライバー遺伝子 / 化学療法 / 分子標的治療 |
Outline of Final Research Achievements |
Efficacy of chemotherapy or presence of targetable genomic alterations has remained unclear in pulmonary sarcomatoid carcinomas. Development of therapeutic strategies for this entity is an important issue. Biomarker analysis is being conducted with next generation sequencer in parallel with our prospective phase 2 study which prospectively examines the efficacy of chemotherapy in pulmonary sarcomatoid carcinomas. So far 15 patients have been enrolled onto this study (target patient number; 30), and we are conducting the biomarker analysis employing the tissue materials from the enrolled patients.
|
Report
(4 results)
Research Products
(12 results)
-
[Journal Article] Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations.2018
Author(s)
Oizumi S, Sugawara S, Minato K, Harada T, Inoue A, Fujita Y, Maemondo M, Watanabe S, Ito K, Gemma A, Demura Y, Fukumoto S, Isobe H, Kinoshita I, Morita S, Kobayashi K, Hagiwara K, Aiba K, Nukiwa T.
-
Journal Title
ESMO Open
Volume: 3(2)
Issue: 2
Pages: e000313-e000313
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
[Journal Article] A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002)2017
Author(s)
Ikezawa Y, Asahina H, Oizumi S, Watanabe M, Takamura K, Kawai Y, Yamada N, Harada T, Kinoshita I, Fujita Y, Miyauchi E, Ogi T, Amano T, Furuta M, Sakakibara-Konishi J, Nishihara H, Dosaka-Akita H, Isobe H, Nishimura M; Hokkaido Lung Cancer Clinical Study Group
-
Journal Title
Cancer Chemother Pharmacol
Volume: 80
Issue: 5
Pages: 955-963
DOI
NAID
Related Report
Peer Reviewed / Int'l Joint Research
-
[Journal Article] Immunohistochemical profiling of receptor tyrosine kinases, MED12, and TGF-βRII of surgically resected small cell lung cancer, and the potential of c-kit as a prognostic marker2016
Author(s)
Yokouchi H, Nishihara H, Harada T, Ishida T, Yamazaki S, Kikuchi H, Oizumi S, Uramoto H, Tanaka F, Harada M, Akie K, Sugaya F, Fujita Y, Takamura K, Kojima T, Higuchi M, Honjo O, Minami Y, Watanabe N, Goto A, Suzuki H, Dosaka-Akita H, Isobe H, Nishimura M, Munakata M
-
Journal Title
Oncotarget
Volume: Dec 31
Issue: 24
Pages: 39711-39726
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] rognostic impact of clinical variables on surgically resected small-cell lung cancer: Results of a retrospective multicenter analysis (FIGHT002A and HOT1301A)2015
Author(s)
Yokouchi H, Ishida T, Yamazaki S, Kikuchi H, Oizumi S, Uramoto H, Tanaka F, Harada M, Akie K, Sugaya F, Fujita Y, Fukuhara T, Takamura K, Kojima T, Harada T, Higuchi M, Matsuura Y, Honjo O, Minami Y, Watanabe N, Nishihara H, Suzuki H, Dosaka-Akita H, Isobe H, Nishimura M, Munakata M
-
Journal Title
Lung Cancer
Volume: 90
Issue: 3
Pages: 548-53
DOI
Related Report
Peer Reviewed / Acknowledgement Compliant
-
-
[Journal Article] First-line gefitinib for elderly patients with advanced NSCLC harboring EGFR mutations. A combined analysis of North-East Japan Study Group studies.2015
Author(s)
Morikawa N, Minegishi Y, Inoue A, Maemondo M, Kobayashi K, Sugawara S, Harada M, Hagiwara K, Okinaga S, Oizumi S, Nukiwa T, Gemma A; North-East Japan Study Group.
-
Journal Title
Expert Opin Pharmacother.
Volume: 16(4)
Issue: 4
Pages: 465-72
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.2015
Author(s)
Sugawara S, Oizumi S, Minato K, Harada T, Inoue A, Fujita Y, Maemondo M, Yoshizawa H, Ito K, Gemma A, Nishitsuji M, Harada M, Isobe H, Kinoshita I, Morita S, Kobayashi K, Hagiwara K, Kurihara M, Nukiwa T; North East Japan Study Group and Tokyo Cooperative Oncology Group
-
Journal Title
Ann Oncol.
Volume: 26(5)
Issue: 5
Pages: 888-94
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 07022015
Author(s)
.Inoue A, Sugawara S, Maemondo M, Mori Y, Oizumi S, Harada M, Taima K, Morikawa N, Ishida T, Kinoshita I, Watanabe H, Suzuki T, Nakagawa T, Saito R, Nukiwa T
-
Journal Title
Lung Cancer
Volume: 89
Issue: 1
Pages: 61-5
DOI
Related Report
Peer Reviewed
-
[Journal Article] Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002)2015
Author(s)
Miyauchi E, Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Saijo Y, Yoshizawa H, Hagiwara K, Nukiwa T; North-East Japan Study Group
-
Journal Title
Jpn J Clin Oncol
Volume: 45
Issue: 7
Pages: 670-6
DOI
Related Report
Peer Reviewed / Open Access
-
-
-